Clinical Trial Update: A Bioequivalence Study of 15 mg ER OROS Paliperidone [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of 15 mg extended-release OROS paliperidone in schizophrenia has completed. Sponsored by Johnson & Johnson Pharmaceutical Research …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA (PALIPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED